cancer

Gilead Sci­ences said Mon­day morn­ing that Trodelvy is the first TROP-2 di­rect­ed ADC to show sta­tis­ti­cal­ly sig­nif­i­cant and “clin­i­cal­ly mean­ing­ful” re­sults in over­all sur­vival from a sec­ond in­ter­im analy­sis of a Phase 3 tri­al in pa­tients with HR+/HER2- metasta­t­ic breast can­cer who re­ceived pri­or en­docrine ther­a­py, CDK4/6 in­hibitors and two to four lines of chemo. …

Gilead’s Trodelvy scores ‘surprise’ OS win in metastatic breast cancer, but data will wait for an upcoming conference – Endpoints News Read More »